Today, on 3rd April 2025, drug and pharmaceutical companies were exempted from reciprocal tariffs from the US. Lupin witnessed a 4% rise following the announcement. The company also declared its plan to acquire the UK-based Renascience Pharma.
Lupin announced that its subsidiary, Lupin Healthcare, will be directly involved in the acquisition, worth 12.3 million pounds. This deal made Lupin the owner of Renascence Pharma and its four specialty pharmaceutical products.
Fabrice Egros, Lupin’s President of Corporate Development, said the company aims to expand its branded medicine base in the UK while providing affordable and sustainable healthcare solutions to those with unmet health needs.
Renascience co-founder and director Eric Che commented on the acquisition. He stated that it would help enlarge the company’s reach and improve its business. Lupin’s shares opened to the market at Rs. 2,100.00 and are currently up by 4.5% compared to the previous session’s close of Rs. 2,009.70.
Lupin’s Share Price in Today’s Market
At 11:45 a.m., Lupin Pharma traded its shares at Rs 2.098.85, nearly 4.45% higher than its previous close. According to the reports and estimates on Money Control, the current market capitalization shows 95,814 cores; the UC Limit is 2,210.65, and the LC Limit is 1,808.75.
Company Financials
Lupin’s third quarter financials report that the company earned a revenue of Rs. 5,768 crore, an 11% increase compared to Rs. 5,197 crore in Q3 FY2024. Its EBITDA stood at Rs. 1,366 crore, a 33.6% rise from Rs. 1,022 crore in Q3 FY2024. Lupin’s Profit Before Tax (PBT): Rs. 1,071 crore, marking a 45.5% year-on-year increase, and Profit After Tax (PAT) was Rs. 859 crore, a 39.5% increase compared to the previous year’s quarter.
Recent News About Lupin Pharma
- In April, to improve healthcare systems in Jaipur, the Lupin Human Welfare & Research Foundation and the State Health Department collaborated to host a two-day state-level workshop.
Lupin Pharma Share Price Target
As market analysts on Trendlyne indicated, Lupin Ltd. has an average target of 2329.44. The consensus estimated an upside of 11.22% from the last price of 2094.50.
Should You Buy, Sell, Or Hold?
Market experts on Trendlyne are divided between holding and buying the shares. On MoneyControl, 39% of analysts recommend buying, and 31% suggest holding the shares. But before investing in Lupin Pharma, consider its long-term performance and consult your analyst to make the perfect move.
